When a cancer cell leaves the original tumor to spread to a new, faraway location, it first has to survive what most cells ...
The FDA is considering whether to conditionally approve a new treatment for DMD patients with mutations amenable to exon 51 ...
Investor's Business Daily on MSN
Sarepta skids after a rival clears a key hurdle in the Duchenne space
Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients.
If approved after priority review, the firm anticipates launching DYNE-251 in the US in the first quarter of next year.
Dyne Therapeutics is a clinical-stage company among biotech stocks that aims to treat rare, genetically driven diseases through its proprietary FORCE platform. It is currently developing therapies for ...
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
达因笔(Dyne Test Pen)能准确地测试出塑料薄膜之张力是否达到试笔的数值,令使用者清楚了解此薄膜是否适合于印刷、复合、或真空镀铝,有效地控制质量及减少因材质不合格所造成的损失。
USC freshman Alijah Arenas is among the 44 prospects invited to the 2026 G League combine, which will take place May 8-10 at the Wintrust Arena in Chicago, Illinois. Arenas averaged 14.1 points, 2.9 ...
USC center Gabe Dynes plans to enter the NCAA Transfer Portal. The 7-foot-5 junior has one season of eligibility remaining. Dynes transferred to USC last offseason. In his lone campaign with the ...
TROY, NY, UNITED STATES, February 5, 2026 /EINPresswire.com/ — Inspect Point, the leading SaaS platform for fire and life safety inspection, testing, and compliance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results